Mometasonfuroat Aristo (Mometasone Furoate Ph. Eur.)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, inhibiting the release of inflammatory mediators such as cytokines and histamine. This action decreases swelling, mucus production, and the allergic response within the nasal passages.

The prescribed dose is determined by the treating clinician based on the patient’s age, severity of symptoms, and response to therapy. Typical regimens involve one or two sprays per nostril once daily, but exact instructions must come from a qualified healthcare professional.

Safety data are limited. Pregnant or breastfeeding individuals should discuss potential risks and benefits with their healthcare provider before using the product, as systemic absorption, though low, could affect the fetus or infant.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and import documentation.

Mometasone furoate is a high‑potency, once‑daily nasal corticosteroid with a low systemic bioavailability, similar to fluticasone propionate. Clinical studies suggest comparable efficacy in symptom control, while the once‑daily dosing of mometasone may improve adherence for some patients.

Store the nasal spray at room temperature, preferably below 25 °C. Keep the device in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is securely closed when not in use to maintain sterility.

Tilt the head slightly forward, insert the nozzle into one nostril, and close the opposite nostril with a finger. Spray the prescribed number of sprays while breathing in gently, then repeat in the other nostril if directed. Avoid blowing the nose immediately after administration.

Serious but rare risks include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek medical attention if they notice unusual bleeding, persistent pain, or signs of systemic corticosteroid effects.

Individuals with known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in patients with active untreated fungal, viral, or bacterial infections of the nasal passages until the infection is resolved.